Document is current
Any future updates will be listed below
-
Authors
Battipaglia, Giorgia https://orcid.org/0000-0002-0695-3879
Wehr, Claudia https://orcid.org/0000-0002-5037-6175
Admiraal, Rick https://orcid.org/0000-0003-1512-2791
Nierkens, Stefan https://orcid.org/0000-0003-3406-817X
Malard, Florent https://orcid.org/0000-0002-3474-0002
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Onida, Francesco https://orcid.org/0000-0002-2991-3474
Sanchez-Ortega, Isabel https://orcid.org/0009-0005-5519-9154
Ruggeri, Annalisa https://orcid.org/0000-0002-7261-2765
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
Kuball, Jürgen https://orcid.org/0000-0002-3914-7806
- License Information
-
More Information
Article History
Received: 6 August 2025
Revised: 23 September 2025
Accepted: 23 October 2025
First Online: 26 November 2025
Competing interests
: ALR: reports honoraria from Gilead. CW: reports honoraria or travel support from Jazz Pharmaceuticals and Mundipharma, and is receiving a research grant from Takeda. FM: reports honoraria from BMS, Therakos, AstraZeneca, MSD, Sanofi, Priothera, and Novartis. FO: reports honoraria from Takeda, Kyowa Kirin, and Medac Pharma; and support for attending meetings from Jazz Pharmaceuticals and Kyowa Kirin. GB: reports honoraria from Sanofi. ISO: Not reported. IYA: received honoraria from Novartis, Gilead/Kite, BMS, and Pfizer. He declares no conflict of interest related to this work. JK: is cofounder and shareholder of Gadeta Founders B.V., inventor on patents related to γδTCR/ligand and genetic engineering, and has received research funding from Novartis, Miltenyi Biotech, and Gadeta. For full disclosure, see: . MM reports honoraria and/or serving on advisory boards for Adaptive Biotechnologies, Amgen, Astellas Pharma, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Cilag EMEA, Jazz Pharmaceuticals, MEDAC PHARMA, INC., Novartis, OncoPep, Inc., Pfizer, Sanofi, Stemline Therapeutics Inc., Takeda Oncology, and Therakos. He has also received research grants from Janssen Cilag EMEA, Jazz Pharmaceuticals, and Sanofi. Dr. Mohty serves as a board member (volunteer, no compensation) for the EBMT, Intergroupe Francophone du Myelome, International Academy for Clinical Hematology, and the International Myeloma Society. He is a journal editor for Springer (receives honoraria) and holds academic positions at Assistance Publique - Hôpitaux de Paris and Université Sorbonne Paris Cité. RA: reports an unrestricted research grant from Sanofi. RZ: reports honoraria from Novartis, Incyte, Medac, Sanofi, and Neovii. SN: Not reported.
